新辅助放化疗后具核梭杆菌持续存在与局部晚期直肠癌复发风险
该研究分析了143例局部晚期直肠癌患者共254份样本,用RNA原位杂交和数字图像分析定量具核梭杆菌。结果显示新辅助放化疗后具核梭杆菌阳性而非基线状态显著增加复发风险(HR=7.5,95%CI 3.0-19.0,P<0.001),且与CD8+ T细胞诱导缺失相关。
要点
- 新辅助放化疗后具核梭杆菌阳性者复发风险显著升高(HR=7.5)。
- 基线具核梭杆菌水平与病理完全缓解无关。
- 放化疗后转为具核梭杆菌阴性者CD8+ T细胞显著增加。
核心结论
- 新辅助放化疗后具核梭杆菌持续存在与局部晚期直肠癌高复发率相关,可能与免疫细胞毒性抑制有关。
研究设计与样本
- 回顾性分析143例直肠腺癌患者共254份样本,使用RNA原位杂交和数字图像分析定量具核梭杆菌。
- 配对分析71例新辅助放化疗前后样本评估治疗诱导变化,45例配对样本进行免疫微环境分析。
主要发现
- RNA原位杂交与定量PCR高度相关(r=0.804,P<0.001)。
- 未治疗肿瘤具核梭杆菌丰度中位数7.4(95%CI 3.7-16.2),治疗后中位数1.6(95%CI 1.3-2.4),P<0.001。
- 未治疗和治疗后阳性率分别为58%(73/126)和26%(22/85),P<0.001。
- 新辅助放化疗后具核梭杆菌阳性显著增加复发风险(HR=7.5,95%CI 3.0-19.0,P<0.001),基线状态无此关联。
- 放化疗后转为具核梭杆菌阴性者CD8+ T细胞显著增加(P<0.001),持续阳性者无显著诱导(P=0.69)。
临床怎么用
- 新辅助放化疗后检测具核梭杆菌状态可能有助于识别高复发风险的局部晚期直肠癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accumulating evidence has identified Fusobacterium as an important pathogenic gut bacterium associated with colorectal cancer. Nevertheless, only limited data exist about the role of this bacterium in locally advanced rectal cancer (LARC). In this study, we quantified Fusobacterium nucleatum in untreated and post-neoadjuvant chemoradiotherapy (nCRT) samples from LARC patients and investigated its association with therapy response and survival. PATIENTS AND METHODS: A total of 254 samples from 143 patients with rectal adenocarcinomas were analyzed for the presence and abundance of F. nucleatum using RNA in situ hybridization and digital image analysis. Assay accuracy was determined using infected cell lines and tumor samples with available quantitative PCR data. We studied the impact of F. nucleatum load on pathologic complete response and relapse-free survival. Treatment-induced changes were evaluated in paired pre- and post-nCRT samples (n = 71). Finally, tumor microenvironment changes during nCRT were assessed in paired samples (n = 45) by immune contexture analysis. RESULTS: F. nucleatum tissue levels by RNA in situ hybridization strongly correlated with quantitative PCR (r = 0.804, P < 0.001). F. nucleatum abundance was higher in untreated [median, 7.4; 95% confidence interval (3.7-16.2)] compared with treated [median, 1.6; 95% confidence interval (1.3-2.4)] tumors (P <0.001) with 58% (73/126) and 26% (22/85) positive tumors, respectively (P < 0.001). Baseline F. nucleatum levels were not associated with pathologic complete response. F. nucleatum positivity after nCRT, but not baseline status, significantly increased risk of relapse [hazard ratio = 7.5, 95% confidence interval (3.0-19.0); P < 0.001]. Tumors that turned F. nucleatum-negative after nCRT had a strong increase in CD8+ T cells post-nCRT (P < 0.001), while those that persisted F. nucleatum-positive after nCRT lacked CD8+ T cells induction in post-nCRT samples compared with baseline (P = 0.69). CONCLUSION: F. nucleatum persistence post-nCRT is associated with high relapse rates in LARC, potentially linked to suppression of immune cytotoxicity.
引用
- Serna G, Ruiz-Pace F, Hernando J, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020. PMID: 32569727. doi:10.1016/j.annonc.2020.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。